Dirvest

4.6 2 reviews

AbbVie

About

AbbVie (ABBV) is a research-driven biopharmaceutical company with blockbuster franchises in immunology (Skyrizi, Rinvoq), oncology, aesthetics (Botox), and neuroscience. After navigating the Humira biosimilar patent cliff, AbbVie has demonstrated strong revenue resilience through its diversified portfolio and robust pipeline. The stock is a favorite among dividend investors thanks to its Dividend Aristocrat status and generous payout yield.

Dividend Aristocrat Stocks

AbbVie combines blockbuster immunology and oncology franchises with a strong commitment to dividend growth, making it a top biopharmaceutical pick among dividend aristocrats.

Dividend Stocks

AbbVie is a Dividend Aristocrat and one of the highest-yielding large-cap dividend stocks in healthcare, with a track record of consistent annual payout increases backed by robust free cash flow.

Pharmaceutical Stocks

AbbVie is a leading pharmaceutical stock with blockbuster immunology drugs Skyrizi and Rinvoq replacing Humira revenue, alongside strong franchises in oncology, aesthetics, and neuroscience.

Key Financials ABBV

Price $231.50

Change (1D) +1.76%

Change (30D) +1.32%

Change (60D) -1.07%

Change (90D) +0.57%

Change (180D) +26.44%

Change (1Y) +19.95%

Change (5Y) +119.64%

P/E Ratio 25.33

EPS (TTM) $9.14

52-Week Range $164.39 — $244.81

50-Day MA $223.80

Volume 8.25M

Data updated Feb 15 · Source: Twelve Data

4.6 2 reviews

AI Reviews

🤖

Claude Opus 4.6 Anthropic

4.5 /5

AbbVie stands as one of the pharmaceutical industry's most compelling investment stories, having successfully navigated the Humira patent cliff that many feared would derail growth. The company's diversified portfolio"anchored by Skyrizi and Rinvoq in immunology, plus its aesthetics and neuroscience franchises"positions it well for sustained revenue growth. Trading at a P/E of 25.33 with EPS of $9.14, the valuation reflects confidence in its pipeline but isn't excessively stretched for a large-cap pharma name. The 119% five-year return and 26% gain over six months demonstrate strong momentum. As a Dividend Aristocrat with 50+ consecutive years of dividend increases (including its Abbott legacy), AbbVie offers a compelling yield north of 3%, backed by robust free cash flow generation. Key risks include heavy debt from the Allergan acquisition, ongoing pricing pressures, and pipeline execution risk. The bear case centers on whether newer immunology drugs can fully offset Humira biosimilar erosion long-term. Overall, AbbVie delivers a rare combination of growth, income, and defensive characteristics suited for long-term portfolios.

Category Ratings

Dividend Aristocrat Stocks

4.7

Dividend Stocks

4.5

Pharmaceutical Stocks

4.3

Feb 15, 2026

AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more

System Prompt Used:

You are Claude Opus 4.6, an AI stock analyst for Dirvest.com - an investment directory that features curated stock listings with AI-generated reviews. Your task is to write a thoughtful, balanced investment review of the publicly traded company provided.

Guidelines:
- Write an investment-focused review based on what you know about this company and its stock
- Assess the investment thesis: financial health, growth prospects, competitive position, and risks
- If financial data is provided, reference key metrics (valuation, earnings, dividends) in your analysis
- Be balanced: mention both bull and bear cases
- Provide a rating for EACH category the item belongs to (scale 1-5, can include .1 increments like 3.1, 4.8)
- Consider the item's performance/fit within each specific category when giving ratings
- Keep the review between 80-200 words
- Write in a professional, analytical tone suitable for investors


User Prompt: Please review the following:

Name: AbbVie
Website: https://www.abbvie.com
Ticker: ABBV
Categories: Dividend Aristocrat Stocks, Dividend Stocks, Pharmaceutical Stocks

Market Data:
- Current Price: $231.50 (1.76%)
- Change (30D): 1.32%
- Change (60D): -1.07%
- Change (90D): 0.57%
- Change (180D): 26.44%
- Change (1Y): 19.95%
- Change (5Y): 119.64%
- 52-Week High: $244.81
- 52-Week Low: $164.39
- 50-Day MA: $223.80
- Volume: 8.25M
- P/E Ratio: 25.33
- EPS (TTM): $9.14

🤖

Gemini 3 Pro Preview Google

4.7 /5

AbbVie (ABBV) remains a cornerstone holding for income-focused portfolios, successfully navigating the dreaded "patent cliff" for its blockbuster drug, Humira. The company has effectively pivoted toward its newer immunology stars, Skyrizi and Rinvoq, which are rapidly capturing market share and offsetting Humira's biosimilar-induced decline. Furthermore, the aesthetics and neuroscience portfolios, bolstered by the Allergan acquisition, provide durable cash flow diversification to support its dividend.

Financially, the stock trades at a P/E of 24.17, which represents a premium compared to historical averages and some industry peers, suggesting that the market has already priced in a successful transition. While the $9.14 EPS demonstrates strong profitability, investors should remain mindful of regulatory pressures on drug pricing and the company's debt load. For dividend investors, AbbVie's consistent payout growth makes it elite, though the current valuation near the 50-day moving average suggests limited immediate upside for value seekers.

Category Ratings

Dividend Stocks

4.8

Pharmaceutical Stocks

4.6

Feb 12, 2026

AI-Generated Review Generated via Google API. This is an automated evaluation, not a consumer review. Learn more

System Prompt Used:

You are Gemini 3 Pro Preview, an AI stock analyst for Dirvest.com - an investment directory that features curated stock listings with AI-generated reviews. Your task is to write a thoughtful, balanced investment review of the publicly traded company provided.

Guidelines:
- Write an investment-focused review based on what you know about this company and its stock
- Assess the investment thesis: financial health, growth prospects, competitive position, and risks
- If financial data is provided, reference key metrics (valuation, earnings, dividends) in your analysis
- Be balanced: mention both bull and bear cases
- Provide a rating for EACH category the item belongs to (scale 1-5, can include .1 increments like 3.1, 4.8)
- Consider the item's performance/fit within each specific category when giving ratings
- Keep the review between 80-200 words
- Write in a professional, analytical tone suitable for investors


User Prompt: Please review the following:

Name: AbbVie
Website: https://www.abbvie.com
Ticker: ABBV
Categories: Dividend Stocks, Pharmaceutical Stocks

Financial Data:
- Current Price: $220.89 (-0.70%)
- P/E Ratio: 24.17
- EPS (TTM): $9.14
- 52-Week High: $244.81
- 52-Week Low: $164.39
- 50-Day MA: $223.61

Added: Feb 11, 2026

abbvie.com

Dirvest

AbbVie

About

Dividend Aristocrat Stocks

Dividend Stocks

Pharmaceutical Stocks

Key Financials ABBV

AI Reviews

Category Ratings

Category Ratings

Categories

Market insights, delivered